CYC, page-15

Comparing CTLVAS to CVLVAS

4DMedical's CT Lung Ventilation Analysis Software (CT LVAS) represents a significant advancement in respiratory diagnostics. Approved by the U.S. FDA in late 2023, CT LVAS builds on 4DMedical's existing X-ray-based technology but leverages CT imaging to offer a more detailed analysis of lung function. The software processes standard CT scans with algorithms derived from aerospace technology to generate high-resolution, color-coded visualizations of lung ventilation. These include quantitative data on lung volume changes and regional ventilation patterns, which could assist clinicians in diagnosing and monitoring respiratory conditions with greater precision.

An exciting aspect of CT LVAS is its compatibility with future software developments like CT:VQ, which will integrate ventilation and perfusion data into a comprehensive assessment of lung performance. This capability has the potential to set new standards in respiratory diagnostics by enabling detailed insights into conditions such as chronic obstructive pulmonary disease (COPD) and asthma【47†source】【48†source】.

When compared to Cyclopharm's Technegas, 4DMedical's CT LVAS may appeal to facilities already equipped with advanced CT systems. While Technegas provides an efficient and well-established solution for ventilation/perfusion (V/Q) imaging in nuclear medicine, CT LVAS offers a non-radioactive, potentially faster option with broader diagnostic applications. This could make it particularly attractive to radiology departments seeking to diversify their respiratory imaging capabilities. However, Technegas's established global presence and its robust performance in V/Q imaging for pulmonary embolism still position it as a strong competitor in the respiratory imaging market.